IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11525008 B1

PDFFull Text
Date of Patent:
Dec. 13, 2022

Filed:

Sep. 21, 2017

Methods and pharmaceutical compositions for the treatment of lung cancer

Applicants:

Inserm (Institut National DE LA Santé ET DE LA Recherche Médicale), Paris, FR;

Université DE Reims Champagne-ardenne, Reims, FR;

Centre Hospitalier Universitaire DE Reims, Reims, FR;

Inventors:

Béatrice Raby, Reims, FR;

Amina Jouida, Reims, FR;

Myriam Polette, Reims, FR;

Assignees:

INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), Paris, FR;

UNIVERSITÉ DE REIMS CHAMPAGNE-ARDENNE, Reims, FR;

CENTRE HOSPITALIER UNIVERSITAIRE DE REIMS, Reims, FR;

Attorney:

WCF IP

Primary Examiner:

Karen A Canella

Int. Cl.
CPC ...
C07K 16/30 (2006.01); A61P 35/00 (2006.01); A61K 31/05 (2006.01); A61K 31/137 (2006.01); A61K 31/255 (2006.01); A61K 31/4706 (2006.01); A61K 31/506 (2006.01); A61K 31/517 (2006.01); A61K 31/519 (2006.01); A61K 31/5355 (2006.01); C12Q 1/6886 (2018.01);
U.S. Cl.
CPC ...
C07K 16/30 (2013.01); A61K 31/05 (2013.01); A61K 31/137 (2013.01); A61K 31/255 (2013.01); A61K 31/4706 (2013.01); A61K 31/506 (2013.01); A61K 31/517 (2013.01); A61K 31/519 (2013.01); A61K 31/5355 (2013.01); A61P 35/00 (2018.01); C12Q 1/6886 (2013.01); C12Q 2531/113 (2013.01); C12Q 2561/113 (2013.01); C12Q 2565/101 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/158 (2013.01);
Abstract

The present invention relates to methods and pharmaceutical compositions for the treatment of lung cancer. The inventors showed that FHIT (also known as bis(5-adenosyl)-triphosphatase) regulates HER2 activity in lung tumor cells and that HER2 inhibitors reduce invasion induced by FHIT inhibition. In particular, the present invention relates to a method of treating lung cancer in a patient in need thereof comprising the steps of i) determining the expression level of FHIT in a tumor tissue sample obtained from the patient, ii) comparing the expression level determined at step i) with a predetermined reference value and iii) administering to the patient a therapeutically effective amount of at least one HER2 inhibitor when the expression level determined at step i) is lower than the predetermined reference level.

Find Patent Forward Citations

Loading…